Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, regarding the utilization of proceeds from its Rights Issue. The report confirms that there has been no deviation from the objects of the issue.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32, confirming no deviation or variation in use of proceeds raised through Rights Issue. The company has utilized Rs. 333.61 crores for repayment or pre-payment of outstanding borrowings and Rs. 112.24 crores for general corporate purposes, which does not exceed 25% of the gross proceeds.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the exchange about the allotment of 2,250 equity shares to employees under the Solara Employee Stock Option Plan 2018.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has appointed Mr. Ajit Manocha as Chief Information Officer (CIO) and Senior Management Personnel with effect from August 10, 2026.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has reported strong Q1'27 base business performance with continued growth and profitability. The company's overall revenues stood at INR 3,843 Mn, up 20% YoY, with EBITDA at INR 635 Mn, up 10% YoY, and PAT at INR 163 Mn, marking the highest EBITDA and PAT reported over the last eighteen quarters.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the exchange about the outcome of its board meeting held on July 23, 2026, where the board considered and approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the limited review report.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has scheduled a conference call with analysts/investors to discuss its unaudited financial results for the quarter ended June 30, 2026.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the Exchange about a newspaper advertisement for a Final Reminder-cum-Forfeiture Notice for payment of Call Money to partly paid Equity shareholders.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the Exchange about approval of Reminder-cum-Forfeiture Notice by the Rights Issue Committee members, to be issued to the partly paid shareholders.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has published a newspaper advertisement regarding the dispatch of notices to shareholders for the transfer of equity shares to the Investor Education and Protection Fund (IEPF) in respect of the unclaimed and unpaid dividend for the financial year 2018-19.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has issued a notice to shareholders regarding the transfer of unclaimed and unpaid dividend for the financial year 2018-19 to the Investor Education and Protection Fund (IEPF) Authority. Shareholders who have not claimed the dividend amounts for a consecutive period of 7 years will have their shares transferred to the IEPF Authority on September 10, 2026, and will no longer be entitled to future benefits, including dividends.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in the securities of the Company shall be closed with effect from Wednesday, July 1, 2026, till 48 hours from the date of declaration of financial results of the Company for the quarter ended June 30, 2026.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has announced that Crisil Ratings Limited has upgraded its credit ratings for bank loan facilities totaling Rs. 791.2 Crore. The long-term rating has been upgraded to 'Crisil BBB+/Stable' from 'Crisil BBB/Stable', and the short-term rating has been upgraded to 'Crisil A2' from 'Crisil A3+'. This upgrade reflects an improvement in the company's financial risk profile and creditworthiness.